Neovasc Announces Partial Prepayment of Convertible Debenture
British Columbia and Minneapolis, Minnesota--(Newsfile Corp. - July 23, 2020) - Neovasc Inc. (NASDAQ: NVCN) (TSX: NVCN) ("Neovasc" or the "Company") announced today that Strul Medical Group LLC ("SMG") exercised 1,424,049 of the 2,573,959 common share purchase warrants (the "May Warrants") issued pursuant to a Securities Purchase Agreement dated May 26, 2020 at an exercise price of US$2.634 per May Warrant for aggregate exercise proceeds to the Company of US$3,750,945.07 (the "Exercise...
2020-07-23 4:23 PM EDT
Neovasc Announces Circulatory System Devices Panel Meeting Date for Neovasc Reducer(TM) Device
British Columbia and Minneapolis, Minnesota--(Newsfile Corp. - July 9, 2020) - Neovasc, Inc. (NASDAQ: NVCN) (TSX: NVCN) ("Neovasc" or the "Company"), announced today that it has been informed by the U.S. Food and Drug Administration (FDA) that the Circulatory System Devices Panel of the Medical Devices Advisory Committee will review the premarket approval application (PMA) for the Neovasc Reducer™ device ("Reducer") at its October 27, 2020 meeting. Neovasc is seeking approval for Reducer in...
2020-07-09 7:30 AM EDT
Neovasc Provides Update on Second Quarter Results
British Columbia and Minneapolis, Minnesota--(Newsfile Corp. - July 6, 2020) - Neovasc, Inc. (NASDAQ: NVCN), (TSX: NVCN) today announced preliminary revenue results for the second quarter of 2020. Revenue for the quarter ended June 30, 2020 was approximately $295,000. Revenues were negatively impacted by a reduction in Reducer procedures that began in mid-March and persisted through early June. Despite a marked slowdown in the number of implants and related revenue from the Reducer because of...
2020-07-06 9:25 AM EDT
Neovasc Reducer(TM) and Tiara(TM) Featured at Leading Industry Virtual Conferences
British Columbia and Minneapolis, Minnesota--(Newsfile Corp. - June 29, 2020) - Neovasc, Inc. (NASDAQ: NVCN), (TSX: NVCN) ("Neovasc" or the "Company"), today announced that the Neovasc Reducer™ ("Reducer") and Tiara™ ("Tiara") program were recently featured at two industry conferences.The Tiara Mitral Valve Replacement program was featured at both the PCR e-Course and the TVT Connect conference.During the courses, Lenard Conradi M.D., University Heart Center Hamburg, Germany, and Gorav...
2020-06-29 12:00 PM EDT
Neovasc Announces Positive Interim Results from REDUCER-I Study
British Columbia and Minneapolis, Minnesota--(Newsfile Corp. - June 26, 2020) - Neovasc Inc. (NASDAQ: NVCN) (TSX: NVCN) ("Neovasc" or the "Company") today announced positive interim results of the REDUCER-I study during the PCR E-Course. Stefan Verheye, MD, PhD, ZNA Middelheim, Antwerp, Belgium presented the results of the trial during the Hotline and Innovation Session.REDUCER-I is a multi-center, international, three-arm prospective and retrospective observational study enrolling up to 400...
2020-06-26 9:45 AM EDT
Neovasc Regains Compliance with Nasdaq Minimum Market Value Rule
British Columbia and Minneapolis, Minnesota--(Newsfile Corp. - June 25, 2020) - Neovasc Inc. (NASDAQ: NVCN) (TSX: NVCN) ("Neovasc" or the "Company") announced that it received written notification yesterday (the "Nasdaq Notice") from the Nasdaq Stock Market LLC ("Nasdaq") notifying the Company that it has regained compliance with the minimum market value requirement set forth in the rules for continued listing on the Nasdaq Capital Market (the "Listing Rules").The Company received a letter...
2020-06-25 9:00 AM EDT
Neovasc Announces Closing of $11.5 Million Registered Direct Offering Priced At-The-Market
British Columbia and Minneapolis, Minnesota--(Newsfile Corp. - June 16, 2020) - Neovasc Inc. (NASDAQ: NVCN) (TSX: NVCN) ("Neovasc" or the "Company"), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies, and minimally invasive devices for the treatment of refractory angina, announced today that it has closed its previously announced registered direct offering (the "Offering") priced at-the-market under Nasdaq rules of an aggregate of 3,883,036...
2020-06-16 2:22 PM EDT
Neovasc Announces $11.5 Million Registered Direct Offering Priced At-The-Market
Vancouver, British Columbia--(Newsfile Corp. - June 12, 2020) - Neovasc Inc. (NASDAQ: NVCN) (TSX: NVCN) ("Neovasc" or the "Company") announced today that it has entered into definitive agreements with certain healthcare-focused institutional investors for the sale of an aggregate of 3,883,036 common shares at a purchase price of US$2.97375 per common share in a registered direct offering (the "Offering") priced at-the-market under Nasdaq rules for aggregate gross proceeds to the Company of...
2020-06-12 9:00 AM EDT
Neovasc Reducer(TM) and Tiara(TM) Program to be Highlighted at Leading Industry Virtual Conferences
British Columbia and Minneapolis, Minnesota--(Newsfile Corp. - June 9, 2020) - Neovasc Inc. (NASDAQ: NVCN) (TSX: NVCN) ("Neovasc" or the "Company") , a leader in the development of minimally invasive transcatheter mitral valve replacement technologies, and minimally invasive devices for the treatment of refractory angina, announced today that the Neovasc Reducer™ ("Reducer") and Tiara™ ("Tiara") program will be featured at two industry conferences this month.At the PCR e-Course, being held...
2020-06-09 9:00 AM EDT
Neovasc Announces Closing of Final Convertible Debt Issuance for Gross Proceeds of US$5.0 Million
British Columbia and Minneapolis, Minnesota--(Newsfile Corp. - June 4, 2020) - Neovasc Inc. (NASDAQ: NVCN) (TSX: NVCN) ("Neovasc" or the "Company"), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies, and minimally invasive devices for the treatment of refractory angina, announced today that, further to its press release dated May 26, 2020, the Company has issued a final convertible note in the principal amount US$1 million to Strul Medical...
2020-06-04 9:00 AM EDT
Neovasc Reducer Spotlighted in Leading German Public Television Program
British Columbia and Minneapolis, Minnesota--(Newsfile Corp. - June 3, 2020) - Neovasc, Inc. (NASDAQ: NVCN) (TSX: NVCN) ("Neovasc" or the "Company"), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies, and minimally invasive devices for the treatment of refractory angina, today announced that the Neovasc Reducer™ device ("Reducer") for the treatment of refractory angina was featured on the Hamburg-based German public television program NDR...
2020-06-03 9:57 AM EDT
Neovasc Has Filed for CE Mark for Tiara TA Transapical Mitral Valve Replacement System
British Columbia and Minneapolis, Minnesota--(Newsfile Corp. - May 27, 2020) - Neovasc, Inc. (NASDAQ: NVCN) (TSX: NVCN) ("Neovasc" or the "Company"), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies, and minimally invasive devices for the treatment of refractory angina, today announced that the Company has filed for CE Mark for its Tiara TA Transapical mitral valve replacement system.Mitral Valve disease is one of the most common forms of...
2020-05-27 10:09 AM EDT
Neovasc Provides Corporate Update
British Columbia and Minneapolis, Minnesota--(Newsfile Corp. - May 26, 2020) - Neovasc, Inc. (NASDAQ: NVCN) (TSX: NVCN) ("Neovasc" or the "Company"), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies, and minimally invasive devices for the treatment of refractory angina, today announced a corporate update on its progress towards its value creation strategies.Fred Colen, Chief Executive Officer of Neovasc, commented, "Today's corporate update...
2020-05-26 5:00 PM EDT
Neovasc Announces Offering of Convertible Debt and Warrants for Gross Proceeds of up to US$5.0 Million, Warrant Exchange Transaction and Repayment of 2017 Convertible Notes and Related Settlement
British Columbia and Minneapolis, Minnesota--(Newsfile Corp. - May 26, 2020) - Neovasc Inc. (NASDAQ: NVCN) (TSX: NVCN) ("Neovasc" or the "Company"), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies, and minimally invasive devices for the treatment of refractory angina, announced today 1) an offering ("Offering") of convertible notes ("2020 Notes") and warrants ("2020 Warrants") to Strul Medical Group for gross proceeds of up to US$5.0...
2020-05-26 4:06 PM EDT
Neovasc Announces First Quarter Financial Results
British Columbia and Minneapolis, Minnesota--(Newsfile Corp. - May 7, 2020) - Neovasc Inc. (NASDAQ: NVCN) (TSX: NVCN) ("Neovasc" or the "Company"), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies, and minimally invasive devices for the treatment of refractory angina, today reported financial results for the first quarter ended March 31, 2020. First Quarter HighlightsFDA formally accepted Reducer PMA applicationRenewal of NUB Status 1...
2020-05-07 4:23 PM EDT
Neovasc Announces Receipt of Nasdaq Extension to Satisfy Market Cap Rule
British Columbia and Minneapolis, Minnesota--(Newsfile Corp. - May 1, 2020) - Neovasc Inc. (NASDAQ: NVCN) (TSX: NVCN) ("Neovasc" or the "Company"), a leader in the development of minimally invasive transcatheter mitral valve replacement and minimally invasive devices for the treatment of refractory angina, today announced that the Nasdaq Hearings Panel has granted the Company's request for an extension through August 17, 2020 to evidence compliance with the $35 million minimum market value of...
2020-05-01 5:00 PM EDT
Neovasc to Report First Quarter Financial Results on May 7, 2020
British Columbia and Minneapolis, Minnesota--(Newsfile Corp. - April 23, 2020) - Neovasc, Inc. (NASDAQ: NVCN) (TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and minimally invasive devices for the treatment of refractory angina, today announced that it will report financial results for the quarter ended March 31, 2020 after the market close on May 7, 2020. Neovasc Chief Executive Officer Fred Colen and Chief Financial Officer...
2020-04-23 8:30 AM EDT
Neovasc Announces Fourth Quarter and Full Year 2019 Financial Results
British Columbia and Minneapolis, Minnesota--(Newsfile Corp. - March 30, 2020) - Neovasc Inc. (NASDAQ: NVCN), (TSX: NVCN) ("Neovasc" or the "Company"), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies, the Tiara™ ("Tiara"), and minimally invasive devices for the treatment of refractory angina, the Neovasc Reducer™ ("Reducer") today reported financial results for the fourth quarter and full year ending December 31, 2019.Recent...
2020-03-30 4:05 PM EDT
Neovasc to Report Fourth Quarter and Full Year 2019 Financial Results on March 30, 2020
Vancouver, British Columbia--(Newsfile Corp. - March 17, 2020) - Neovasc, Inc. (NASDAQ: NVCN) (TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and minimally invasive devices for the treatment of refractory angina, today announced that it will report financial results for the quarter and year ended December 31, 2019 after the market close on March 30, 2020. Neovasc CEO Fred Colen and CFO Chris Clark will host a conference call...
2020-03-17 9:00 AM EDT
Neovasc Updates Investors at SVB Leerink 9th Annual Global Healthcare Conference
Vancouver, British Columbia--(Newsfile Corp. - March 4, 2020) - Neovasc, Inc. (NASDAQ: NVCN) (TSX: NVCN) ("Neovasc" or the "Company"), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and minimally invasive devices for the treatment of refractory angina, recaps the presentation by CEO Fred Colen at the SVB Leerink 9th Annual Global Healthcare Conference on Wednesday, February 26, 2020 in New York City.A link to the replay of the...
2020-03-04 9:00 AM EST